Journal of Endocrinological Investigation

, Volume 26, Issue 4, pp 359–363 | Cite as

Development of a meningioma in a patient with acromegaly during octreotide treatment: Are there any causal relationships?

  • E. De Menis
  • G. Tulipano
  • S. Villa
  • D. Billeci
  • C. Bonfanti
  • P. Pollara
  • P. Pauletto
  • Andrea Giustina
Case Report


Somatostatin receptors are highly expressed in almost all meningiomas but in this setting their functional role is not clear. A 59-yrold woman had been treated with octreotide after an unsuccessful operation for a GH-secreting pituitary adenoma. After 8 yr of treatment, a nuclear magnetic resonance (NMR) scan disclosed a 3 cm meningioma of the tentorium. Mean GH was 2.2 ng/ml and IGF-I 325 ng/ml. Meningioma was resected and tissue was digested to obtain tumor cell suspension. Aim of the study was to measure epidermal growth factor (EGF)-induced proliferation of cultured meningioma cells in the presence of either somatostatin or octreotide. Cells were grown to semiconfluency in Dolbecco’s modified eagle medium (D-MEM) supplemented with 10% fetal calf serum (FCS). After 48 h in D-MEM without serum, the medium was replaced by fresh medium plus recombinant EGF (10 ng/ml) and somatostatin or octreotide were added in the final concentrations of 1,10 and 100 nM. 20 h later 1 μcgCi of 3H-thymidine was added to each well. After 4 h, incorporated radioactivity was measured. While octreotide did not influence significantly cell growth at the three dose tested, somatostatin increased thymidine incorporation dose-dependently (peak 100nM: 150%±27% vs medium plus EGF, p<0.05). Octreotide effectively suppressed GH secretion in our acromegalic patient but is unlikely that its long-term use could have stimulated the growth of meningioma since it did not significantly influence the in vitro proliferation of the meningioma cells. These results suggest that somatostatin-mediated proliferative effect on meningioma cells is not mediated by the subtype 2 of the somatostatin receptor.


acromegaly meningioma somatostatin octreotide somatostatin receptors 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Patel Y.C. Somatostatin and its receptor family. Front. Neuroendocrinol. 1999, 20: 157–198.PubMedCrossRefGoogle Scholar
  2. 2.
    Weckbecker G., Raulf F., Stolz B., Bruns C. Somatostatin analogs for diagnosis and treatment of cancer. Pharmacol. Ther. 1993, 60: 245–264.PubMedCrossRefGoogle Scholar
  3. 3.
    Giustina A., Zaltieri G., Negrini F., Wehrenberg W.B. The pharmacological aspects of the treatment of acromegaly. Pharmacol. Res. 1996, 34: 247–268.PubMedCrossRefGoogle Scholar
  4. 4.
    Tulipano G., Bonfanti C., Milani G., et al. Differential inhibition of growth hormone secretion by analogs selective for somatostatin receptor subtypes 2 and 5 in human growth-hormone-secreting adenoma cells in vitro. Neuroendocrinol. 2001, 73: 344–351.CrossRefGoogle Scholar
  5. 5.
    Krenning E.P., Kwekkwboom D.J., Bakker W.H. Somatostatin receptor scintigraphy with [111-DTPA-D-Phe] and [123Tyr3]-octretide: the Rotterdam experience with more than 1000 patients. Eur. J. Nucl. Med. 1993, 20: 716–723.PubMedCrossRefGoogle Scholar
  6. 6.
    Reubi J.C., Maurer R., Klijn J.G.M., et al. High incidence of somatostatin receptors in human meningiomas: biochemical characterization. J. Clin. Endocrinol. Metab. 1986, 63: 433–438.PubMedCrossRefGoogle Scholar
  7. 7.
    Dutour A., Kumar U., Panetta R., et al. Expression of so-matostatin receptor subtypes in human brain tumors. Int. J. Cancer 1998, 76: 620–627.PubMedCrossRefGoogle Scholar
  8. 8.
    Schultz S., Pauli S.U., Schulz S., et al. Immunohistochemical determination of five somatostatin receptors in meningioma reveals frequent overexpression of somatostatin receptor subtype SSTR2A. Clin. Cancer Res. 2000, 6: 1865–1874.Google Scholar
  9. 9.
    Kunert-Radek J., Stepien H., Radek A., Pawlikowski M. Somatostatin suppression of meningioma cell proliferation in vitro. Acta Neurol. Scand. 1987, 75: 434–436.PubMedCrossRefGoogle Scholar
  10. 10.
    Koper J.W., Markstein R., Kohler C., et al. Somatostatin inhibits the activity of adenylate cyclase in cultured human meningioma cells and stimulates their growth. J. Clin. Endocrinol. Metab. 1992, 74: 543–547.PubMedGoogle Scholar
  11. 11.
    Barkan A.L., Lloyd R.V., Chandler W.F., et al. Preoperative treatment of acromegaly with long-acting somatostatin analog SMS 201-995: shrinkage of invasive pituitary macroadenomas and improved surgical remission rate. J. Clin. Endocrinol. Metab. 1988, 67: 1040–1048.PubMedCrossRefGoogle Scholar
  12. 12.
    Kraenzlin M.E., CH’ng J.C.G., Wood S.M., Carr D.H. Long-term treatment of VIPoma with somatostatin analogue resulting in remission of symptoms and possible shrinkage of metastases. Gastroenterology 1985, 88: 185–187.PubMedCrossRefGoogle Scholar
  13. 13.
    Weckebecker G., Tolcsvai L., Stolz B., Pollack M., Bruns C. Somatostatin analogue octreotide enhances the antineo-plastic effect of tamoxifen and ovariectomy on 7, 12-dimethylbenz(a)anthracene-induced rat mammary carcinomas. Cancer Res. 1994, 54: 6334–6337.Google Scholar
  14. 14.
    Runzi M.W., Jaspers C., Windeck R., et al. Successful treatment of meningioma with octreotide. Lancet 1989, 1 (8646): 1074.PubMedCrossRefGoogle Scholar
  15. 15.
    Garcia-Luna P.P., Relimpio F., Pumar A., et al. Clinical use of octreotide in unresectable meningiomas. A report of three cases. J. Neuro. Sci. 1993, 37: 237–241.Google Scholar
  16. 16.
    Jaffrain-Rea M.L., Minniti G., Santoro A., et al. Visual improvement during octreotide therapy in a case of episellar meningioma. Clin. Neurol. Neurosurg. 1998, 100: 40–43.PubMedCrossRefGoogle Scholar
  17. 17.
    Orme S.M., Mcnally R.J.Q., Cartwright R.A., Belchetz P.A. Mortality and cancer incidence in acromegaly: a retrospective cohort study. J. Clin. Endocrinol. Metab. 1998, 83: 2730–2734.PubMedGoogle Scholar
  18. 18.
    Jenkins P.J., Frajese V., Jones A.M., et al. Insulin-like growth factor I and the development of colorectal neo-plasia in acromegaly. J. Clin. Endocrinol. Metab. 2000, 85: 3218–3221.PubMedGoogle Scholar
  19. 19.
    Cannav`o S., Curt`o L., Fazio R., et al. Coexistance of growth-hormone secreting pituitary adenoma and in-tracranial meningioma: a case report and review of the literature. J. Endocrinol. Investig. 1993, 16: 703–708.CrossRefGoogle Scholar
  20. 20.
    Khandwala H.M., McCutcheon I.E., Flyvbjerg A., Friend K.E. The effects of insulin-like growth factors on tumori-genesis and neoplastic growth. Endocr. Rev. 2000, 21: 215–144.PubMedCrossRefGoogle Scholar
  21. 21.
    Kurihara M., Tokunaga Y., Tsutsumi K., et al. Characterization of insulin-like growth factor-I and epidermal growth factor receptors in meningioma. J. Neurosurg. 1989, 71: 538–544.PubMedCrossRefGoogle Scholar
  22. 22.
    Tsutsumi K., Kitigawa N., Niwa M., Himeno A., Taniyama K., Shibata S. Effect of suramin on 125I-IGF-I binding to human meningiomas and on proliferation of meningioma cells. J. Neurosurg. 1994, 80: 502–509.PubMedCrossRefGoogle Scholar
  23. 23.
    Antoniades H.N., Galanopoulos T., Neville-Golden J., Maxwell M. Expression of insulin-like growth factors-I and II and their receptors mRNAs in primary human astrocy-tomas and meningiomas: in vitro studies using in vitro hybridization and immunocytochemistry. Int. J. Cancer 1992, 50: 215–222.PubMedCrossRefGoogle Scholar
  24. 24.
    Lichtor T., Kurpakus M.A., Gurney M.E. Expression of insulin-like growth factors and their receptors in human meningiomas. J. Neuro-oncol. 1993, 17: 183–190.CrossRefGoogle Scholar
  25. 25.
    Friend K.E., Radinski R., McCutcheon I.E. Growth hormone receptor expression and function in meningioma: effects of a specific receptor antagonist. J. Neurosurg. 1999, 91: 93–99.PubMedCrossRefGoogle Scholar
  26. 26.
    McCutcheon I.E., Flyvbjerg A., Hill H., et al. Antitumor activity of the growth hormone receptor antagonist pegvi-somant against human meningiomas in nude mice. J. Neurosurg. 2001, 94: 487–492.PubMedCrossRefGoogle Scholar
  27. 27.
    Giustina A., Barkan A., Casanueva F.F., et al. Criteria for cure of acromegaly: a consensus statement. J. Clin. Endocrinol. Metab. 2000, 85: 526–529.PubMedGoogle Scholar

Copyright information

© Italian Society of Endocrinology (SIE) 2003

Authors and Affiliations

  • E. De Menis
    • 1
  • G. Tulipano
    • 3
  • S. Villa
    • 3
  • D. Billeci
    • 2
  • C. Bonfanti
    • 4
  • P. Pollara
    • 4
  • P. Pauletto
    • 1
  • Andrea Giustina
    • 3
  1. 1.Department of Internal MedicineUniversity of BresciaBresciaItaly
  2. 2.Division of Neurosurgery, Hospital of TrevisoUniversity of BresciaBresciaItaly
  3. 3.Endocrine Section, Department of Internal MedicineUniversity of BresciaBresciaItaly
  4. 4.Institute of Microbiology, Department of Biomedical Sciences and BiotechnologiesUniversity of BresciaBresciaItaly

Personalised recommendations